Sze-Wan Li

The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1<i>R</i>,2<i>S</i>)-2-(3-((<i>E</i>)-4-(((<i>cis</i>)-2,6-Dimethylmorpholino)methyl)styryl)-1<i>H</i>-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Peter B. Sampson, Yong Liu, Bryan Forrest et al. · Journal of Medicinal Chemistry · 2014 · 166 citations · Full text

The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3<i>H</i>]indol]-2′(1′<i>H</i>)-ones as Orally Bioavailable Antitumor Agents

Peter B. Sampson, Yong Liu, Narendra Kumar Patel et al. · Journal of Medicinal Chemistry · 2014 · 109 citations

Pharmaceutical Science, Polo-like Kinase Family, Compound 18 +22

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

Yong Liu, Radoslaw S. Laufer, Narendra Kumar Patel et al. · ACS Medicinal Chemistry Letters · 2016 · 78 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Drug Target +14

The Discovery of PLK4 Inhibitors: (<i>E</i>)-3-((1<i>H</i>-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents

Radoslaw S. Laufer, Bryan Forrest, Sze-Wan Li et al. · Journal of Medicinal Chemistry · 2013 · 71 citations · Full text

Molecular Biology, Pharmacotherapy, Chemical Biology +18

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Zachary Veitch, David W. Cescon, Trisha A. Denny et al. · British Journal of Cancer · 2019 · 66 citations · Full text